Publications by authors named "Ehsan Parvaresh Rizi"

Background: Dapagliflozin improved cardiometabolic outcomes following myocardial infarction in patients without prior type-2 diabetes (T2DM) in the DAPA-MI (dapagliflozin in patients with myocardial infarction) trial. The effect of glycemic status and body mass index (BMI) post-myocardial infarction requires elucidation.

Methods: Participants with T2DM diagnosis, without baseline hemoglobin A1c, or not receiving any study medication, were excluded.

View Article and Find Full Text PDF

Diabetes mellitus affected more than 500 million of people globally, with an annual mortality of 1.5 million directly attributable to diabetic complications. Oxidative stress, in particularly in post-prandial state, plays a vital role in the pathogenesis of the diabetic complications.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluated the effects of dapagliflozin in patients with acute myocardial infarction (MI) who had impaired heart function but no prior diabetes or chronic heart failure.
  • Over 4,000 patients were enrolled, with those taking dapagliflozin showing a significant improvement in a composite outcome of various adverse events compared to the placebo group.
  • Despite these improvements in cardiometabolic outcomes, there was no significant difference in rates of cardiovascular death or hospitalization for heart failure between the two groups, and safety concerns were not identified.
View Article and Find Full Text PDF
Article Synopsis
  • Therapies are needed to prevent heart failure and other cardiovascular problems after a recent heart attack.
  • DAPA-MI is a major clinical trial testing the drug dapagliflozin versus a placebo in patients with heart attack and poor heart function, focusing on outcomes like death and hospitalization for heart failure.
  • The trial aims to improve patient outcomes using an innovative design that leverages existing national clinical registries for efficient data collection and patient recruitment.
View Article and Find Full Text PDF

Aims: To compare time in range (TIR) with use of insulin degludec U100 (degludec) versus insulin glargine U100 (glargine U100) in people with type 2 diabetes.

Materials And Methods: We conducted a randomized, crossover, multicentre trial comparing degludec and glargine U100 in basal insulin-treated adults with type 2 diabetes and ≥1 hypoglycaemia risk factor. There were two treatment periods, each with 16-week titration and 2-week maintenance phases (with evaluation of glucose using blinded professional continuous glucose monitoring).

View Article and Find Full Text PDF

Introduction: Hypoglycaemia is a common side effect of insulin therapy; low or high glycated haemoglobin (HbA) levels, history of hypoglycaemia or long diabetes duration are known modifiers of hypoglycaemia risk. In randomised clinical trials, lower rates of hypoglycaemia have been observed with the new-generation insulin analogue, long-acting insulin degludec, compared with other basal insulins.

Methods: The ReFLeCT study was a prospective observational study over 12 months.

View Article and Find Full Text PDF

Introduction And Objective: Heredity of type 2 diabetes mellitus (T2DM) is associated with greater risk for developing T2DM. Thus, individuals who have a first-degree relative with T2DM (FDRT) provide a natural model to study factors of susceptibility towards development of T2DM, which are poorly understood. Emerging key players in T2DM pathophysiology such as adverse oxidative stress and inflammatory responses could be among possible mechanisms that predispose FDRTs to develop T2DM.

View Article and Find Full Text PDF

Introduction: The objective of this study was to establish the burden of hypoglycemia on family members of people with diabetes (PWDs) and to gain an understanding of how conversations about hypoglycemia can contribute to diabetes care.

Methods: This was a multinational cross-sectional study of family members of people with type 1 or type 2 diabetes taking insulin and/or secretagogues for ≥ 12 months who voluntarily completed an online questionnaire.

Results: Overall, 4300 family members of PWDs (type 1 [29%], type 2 [46%], unknown [25%]) were surveyed.

View Article and Find Full Text PDF

The concentrations of lipoprotein particles [high-density lipoproteins (HDLs), low-density lipoproteins (LDLs), very-low-density lipoproteins (VLDLs), and chylomicrons] are associated with the risk of cardiovascular diseases. Most studies have examined these associations in the fasting state. Previous studies have shown lipoprotein particle concentration change following meal, and these changes are different in individuals with obesity.

View Article and Find Full Text PDF

Oxidative stress induced by nutritional overload has been linked to the pathogenesis of insulin resistance, which is associated with metabolic syndrome, obesity, type 2 diabetes and diabetic vascular complications. Postprandial changes in expression of oxidative stress pathway genes in obese vs. lean individuals, following intake of different types of meals varying in macronutrient composition have not been characterized to date.

View Article and Find Full Text PDF

Although insulin resistance (IR) is a key pathophysiologic condition underlying various metabolic disorders, impaired cellular glucose uptake is one of many manifestations of metabolic derangements in the human body. To study the systems-wide molecular changes associated with obesity-dependent IR, we integrated information on plasma proteins and microRNAs in eight obese insulin-resistant (OIR, HOMA-IR > 2.5) and nine lean insulin-sensitive (LIS, HOMA-IR < 1.

View Article and Find Full Text PDF

It is known that the macronutrient content of a meal has different impacts on the postprandial satiety and appetite hormonal responses. Whether obesity interacts with such nutrient-dependent responses is not well characterized. We examined the postprandial appetite and satiety hormonal responses after a high-protein (HP), high-carbohydrate (HC), or high-fat (HF) mixed meal.

View Article and Find Full Text PDF

Background: Obesity-related insulin resistance is linked to inflammation. Immunometabolic function differs between lean and obese subjects, but whether macronutrient composition of ingested meals affects these responses is not well known. We examined the effects of a single meal rich in fat, protein, or carbohydrate on immunometabolic responses.

View Article and Find Full Text PDF

Background: Obesity is associated with an impaired ability to switch from fatty acid to glucose oxidation during the fasted to fed transition, particularly in skeletal muscle. However, whether such metabolic inflexibility is reflected at the gene transcription level in circulatory mononuclear cells (MNC) is not known.

Methods: The whole-body respiratory quotient (RQ) and transcriptional regulation of genes involved in carbohydrate and lipid metabolism in MNC were measured during fasting and in response (up to 6 h) to high-carbohydrate and high-fat meals in nine lean insulin-sensitive and nine obese insulin-resistant men.

View Article and Find Full Text PDF

Context: Among Asian ethnic groups, Chinese or Malays are more insulin sensitive than South Asians, in particular in lean individuals. We have further reported that body fat partitioning did not explain this ethnic difference in insulin sensitivity.

Objective: We examined whether adipocytokines might explain the ethnic differences in the relationship between obesity and insulin resistance among the three major ethnic groups in Singapore.

View Article and Find Full Text PDF

Background: This study aimed to identify determinants of new onset type-2 diabetes (T2D) and prediabetes in a region with high rate of T2D but scarcity of evidence.

Methods: Participants free of T2D were identified in a population-based study of adults older than 35 years living in the rural and urban areas of three districts in Iran in 2001 and were re-examined after 7 years. Biochemical measurements, anthropometric data, blood pressure, smoking status and dietary intake were determined at both measurement points through identical protocols and procedures.

View Article and Find Full Text PDF

Introduction: To evaluate the clinical profile of BIAsp 30 (30% soluble insulin aspart, 70% protamine-crystallized insulin aspart) (NovoMix®)30) in type 2 diabetes patients in routine clinical practice in Iran.

Material And Methods: IMPROVE™ was a 26-week, multinational, open-label, non-randomized study in patients with type 2 diabetes. The safety and efficacy of BIAsp 30 were assessed at baseline and at 13 and 26 weeks.

View Article and Find Full Text PDF